Literature DB >> 3865926

Muscle fatigue in McArdle's disease studied by 31P-NMR: effect of glucose infusion.

S F Lewis, R G Haller, J D Cook, R L Nunnally.   

Abstract

In muscle phosphorylase deficiency (McArdle's disease) there is an abnormally rapid fatigue during strenuous exercise. Increasing substrate availability to working muscle can improve exercise tolerance but the effect on muscle energy metabolism has not been studied. Using phosphorus-31 nuclear magnetic resonance (31P-NMR) we examined forearm muscle ATP, phosphocreatine (PCr), inorganic phosphate (Pi) and pH in a McArdle patient (MP) and two healthy subjects (HS) at rest and during intermittent maximal effort handgrip contractions under control conditions (CC) and during intravenous glucose infusion (GI). Under CC, MP gripped to impending forearm muscle contracture in 130 s with a marked decline in muscle PCr and a dramatic elevation in Pi. During GI, MP exercised easily for greater than 420 s at higher tensions and with attenuated PCr depletion and Pi accumulation. In HS, muscle PCr and Pi changed more modestly and were not affected by GI. In MP and HS, ATP changed little or not at all with exercise. The results suggest that alterations in the levels of muscle PCr and Pi but not ATP are involved in the muscle fatigue in McArdle's disease and the improved exercise performance during glucose infusion.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3865926     DOI: 10.1152/jappl.1985.59.6.1991

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  11 in total

Review 1.  Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V).

Authors:  Rosaline Quinlivan; Andrea Martinuzzi; Benedikt Schoser
Journal:  Cochrane Database Syst Rev       Date:  2014-11-12

2.  A sugary cocktail for McArdle disease.

Authors:  Michio Hirano
Journal:  Curr Neurol Neurosci Rep       Date:  2005-02       Impact factor: 5.081

3.  Muscle diffusion tensor imaging in glycogen storage disease V (McArdle disease).

Authors:  R Rehmann; L Schlaffke; M Froeling; R A Kley; E Kühnle; M De Marées; J Forsting; M Rohm; M Tegenthoff; T Schmidt-Wilcke; M Vorgerd
Journal:  Eur Radiol       Date:  2018-12-17       Impact factor: 5.315

4.  31P-magnetic resonance spectroscopy assessment of subnormal oxidative metabolism in skeletal muscle of renal failure patients.

Authors:  G E Moore; L A Bertocci; P L Painter
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

5.  Changes in arterial K+ and ventilation during exercise in normal subjects and subjects with McArdle's syndrome.

Authors:  D J Paterson; J S Friedland; D A Bascom; I D Clement; D A Cunningham; R Painter; P A Robbins
Journal:  J Physiol       Date:  1990-10       Impact factor: 5.182

6.  Hexokinase II protein content is a determinant of exercise endurance capacity in the mouse.

Authors:  Patrick T Fueger; Jane Shearer; Tess M Krueger; Kelly A Posey; Deanna P Bracy; Sami Heikkinen; Markku Laakso; Jeffrey N Rottman; David H Wasserman
Journal:  J Physiol       Date:  2005-05-05       Impact factor: 5.182

7.  Exercise intolerance, lactic acidosis, and abnormal cardiopulmonary regulation in exercise associated with adult skeletal muscle cytochrome c oxidase deficiency.

Authors:  R G Haller; S F Lewis; R W Estabrook; S DiMauro; S Servidei; D W Foster
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

8.  Impairment of sympathetic activation during static exercise in patients with muscle phosphorylase deficiency (McArdle's disease).

Authors:  S L Pryor; S F Lewis; R G Haller; L A Bertocci; R G Victor
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

9.  Ca2+-ATPase deficiency in a patient with an exertional muscle pain syndrome.

Authors:  D J Taylor; M J Brosnan; D L Arnold; P J Bore; P Styles; J Walton; G K Radda
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-11       Impact factor: 10.154

10.  Allele copy number and underlying pathology are associated with subclinical severity in equine type 1 polysaccharide storage myopathy (PSSM1).

Authors:  Rosie J Naylor; Leanda Livesey; John Schumacher; Nicole Henke; Claire Massey; Kenny V Brock; Marta Fernandez-Fuente; Richard J Piercy
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.